Global Oncology Academy - Global Oncology Academy

Global Oncology Academy

Global Oncology Academy

Enhance your practice with CME
and tools that focus on the management
and treatment of patients with cancer.

Popular

Updated Overall Survival From Stage 1 of PRESERVE-003: Gotistobart vs Docetaxel in Metastatic Squamous NSCLC After Anti-PD-(L)1 Progression
Updated Overall Survival From Stage 1 of PRESERVE-003: Gotistobart vs Docetaxel in Metastatic Squamous NSCLC After Anti-PD-(L)1 Progression
Oncology and Hematology
Updated Overall Survival From Stage 1 of PRESERVE-003: Gotistobart vs Docetaxel in Metastatic Squamous NSCLC After Anti-PD-(L)1 Progression
Byoung Chul Cho, MD, PhD
- Byoung Chul Cho, MD, PhD
Why Molecular Testing Matters in Non-Small Cell Lung Cancer
Why Molecular Testing Matters in Non-Small Cell Lung Cancer
Project Oncology®
Why Molecular Testing Matters in Non-Small Cell Lung Cancer
Geoffrey Oxnard, MD
- Geoffrey Oxnard, MD
A New Era of Hope in Non-Small Cell Lung Cancer Care
A New Era of Hope in Non-Small Cell Lung Cancer Care
Project Oncology®
A New Era of Hope in Non-Small Cell Lung Cancer Care
Geoffrey Oxnard, MD
- Geoffrey Oxnard, MD
Improving Adherence and Toxicity Monitoring in NSCLC Care
Improving Adherence and Toxicity Monitoring in NSCLC Care
Project Oncology®
Improving Adherence and Toxicity Monitoring in NSCLC Care
Raghava Reddy Induru, MD
- Raghava Reddy Induru, MD
The Importance of Multidisciplinary Coordination in NSCLC Care
The Importance of Multidisciplinary Coordination in NSCLC Care
Project Oncology®
The Importance of Multidisciplinary Coordination in NSCLC Care
Laura Alder, MD
- Laura Alder, MD
Innovations Shaping the Future of Antibody-Drug Conjugates in NSCLC
Innovations Shaping the Future of Antibody-Drug Conjugates in NSCLC
Project Oncology®
Innovations Shaping the Future of Antibody-Drug Conjugates in NSCLC
Christine Bestvina, MD
- Christine Bestvina, MD
Key Questions Shaping Antibody-Drug Conjugate Use in NSCLC
Key Questions Shaping Antibody-Drug Conjugate Use in NSCLC
Project Oncology®
Key Questions Shaping Antibody-Drug Conjugate Use in NSCLC
Laura Alder, MD
- Laura Alder, MD
Emerging Biomarker Research for NSCLC Antibody-Drug Conjugates
Emerging Biomarker Research for NSCLC Antibody-Drug Conjugates
Project Oncology®
Emerging Biomarker Research for NSCLC Antibody-Drug Conjugates
Christine Bestvina, MD
- Christine Bestvina, MD

Medical News

Medical News
Stepped Reminders Boost Lung Cancer Screening Adherence
09/17/2026
Read more
Medical News
Blood mRNA Panel May Detect Early Pancreatic Cancer
09/17/2026
Read more
Medical News
AI Tracks Colorectal Liver Metastases on Follow-up CT
09/17/2026
Read more
Medical News
Sugarbaker Mesh Lowers Parastomal Hernia After APR
09/17/2026
Read more

CME/CE

CME/CE In-Person & Virtual Event
Spotlight on B7-H3 ES-SCLC: Applying ADC Evidence in Real-World Practice
December 5, 2026
Scottsdale, Arizona
1.00 credit
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
MinuteCE®
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
Komal Jhaveri, MD, FACP; Virginia Kaklamani, MD, DSc
0.50 program credits
- Komal Jhaveri, MD, FACP
- Virginia Kaklamani, MD, DSc
0.50 program credits
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
MinuteCE®
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
Komal Jhaveri, MD, FACP; Virginia Kaklamani, MD, DSc
0.50 program credits
- Komal Jhaveri, MD, FACP
- Virginia Kaklamani, MD, DSc
0.50 program credits
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
MinuteCE®
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
Virginia Kaklamani, MD, DSc
0.50 program credits
- Virginia Kaklamani, MD, DSc
0.50 program credits

Clinical Practice

Integrating Molecular Testing into NSCLC Care
Integrating Molecular Testing into NSCLC Care
Project Oncology®
Integrating Molecular Testing into NSCLC Care
Geoffrey Oxnard, MD
- Geoffrey Oxnard, MD
Smarter Screening for Non-Small Cell Lung Cancer
Smarter Screening for Non-Small Cell Lung Cancer
Project Oncology®
Smarter Screening for Non-Small Cell Lung Cancer
Jobelle Baldonado, MD
- Jobelle Baldonado, MD
The Evolving Role of Antibody-Drug Conjugates in NSCLC Care
The Evolving Role of Antibody-Drug Conjugates in NSCLC Care
Project Oncology®
The Evolving Role of Antibody-Drug Conjugates in NSCLC Care
Raghava Reddy Induru, MD
- Raghava Reddy Induru, MD
Antibody-Drug Conjugates for NSCLC: How They Work and Who’s a Candidate
Antibody-Drug Conjugates for NSCLC: How They Work and Who’s a Candidate
Project Oncology®
Antibody-Drug Conjugates for NSCLC: How They Work and Who’s a Candidate
Laura Alder, MD
- Laura Alder, MD

Programs

Managing MAPK Inhibitor Adverse Events in Pediatric Low-Grade Gliomas
Managing MAPK Inhibitor Adverse Events in Pediatric Low-Grade Gliomas
Project Oncology®
Managing MAPK Inhibitor Adverse Events in Pediatric Low-Grade Gliomas
Alexandria May, PharmD, BCPS; Shannon Raber, MS, CPNP, RN
- Alexandria May, PharmD, BCPS
- Shannon Raber, MS, CPNP, RN
- Bridget Archambault, MSN, CPNP
A Patient-First Approach to Smoking Cessation and Lung Cancer Screening
A Patient-First Approach to Smoking Cessation and Lung Cancer Screening
Project Oncology®
A Patient-First Approach to Smoking Cessation and Lung Cancer Screening
Lisa Carter-Bawa, PhD, MPH, APRN, ANP-C, FAAN, FSBM
- Lisa Carter-Bawa, PhD, MPH, APRN, ANP-C, FAAN, FSBM
Managing Antibody-Drug Conjugate Toxicities in NSCLC Care
Managing Antibody-Drug Conjugate Toxicities in NSCLC Care
Project Oncology®
Managing Antibody-Drug Conjugate Toxicities in NSCLC Care
Laura Alder, MD
- Laura Alder, MD
The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
CME/CE Virtual Event
The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
September 29, 2026
12:00 PM - 01:00 PM EDT
1.00 credit